DPP-4

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Kidney, Metabolic acidosis, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis), vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eucreas, vildagliptin,metformin, Date of authorisation: 14/11/2007, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Patient, Liver, Medical Subject Headings, Diarrhea, Marketing, INN, Woman, Allergy, ATC, Absorption, Hormone, Pain, International, Diet, Pancreas, Insulin, Disease, Diabetes, Metformin, Blood, Nausea, Somatic symptom disorder, Language, DPP-4, Type, Glucose, European Medicines Agency, Type 2 diabetes, Food, Metabolic acidosis, Kidney, Tablet, Select, Alcoholism, Anatomy, Vildagliptin, IIA, Exercise, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zomarist, vildagliptin,metformin, Date of authorisation: 30/11/2008, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Marketing, Kidney, European Commission, Diabetes, INN, Risk, Allergy, ATC, Hypoglycemia, Hormone, International, Diet, Pancreas, European, Insulin, Metformin, Disease, Blood, Language, Glycated hemoglobin, DPP-4, Glucose, Type, Tablet, Select, Committee, Patient, Safety, Pioglitazone, Anatomy, Medicine, IIA, CHMP, Exercise, Medical device

Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Trajenta, linagliptin, Date of authorisation: 23/08/2011, Revision: 21, Status: Authorised

Vertex Appoints Nancy Thornberry to its Board of Directors

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, Genetics, Health, Biometrics, New York Genome Center, Chemistry, Senior, Therapy, Sickle cell disease, Biology, GV (company), Patient, Obesity, VRTX, Diabetes, DPP-4, Muhlenberg College, Merck & Co., Cystic fibrosis, Vertex Pharmaceuticals, Pharmaceutical industry, Endocrinology, Science, Vertex, Merck

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director.
  • She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development.
  • “Scientific innovation is a core Vertex value and Nancy brings to our Board deep scientific expertise and a remarkable track record of discovering and developing groundbreaking medicines.
  • And today, they are on the cusp of transforming the treatment of multiple additional serious diseases,” said Nancy Thornberry.

Zydus receives USFDA approval for ZITUVIO™ to treat adult patients with type 2 diabetes mellitus

Retrieved on: 
Friday, October 20, 2023
FDA, DPP-4, Food, USFDA, Diabetes, Nitrosamine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Exercise, Tablet, Type, Zydus Lifesciences, New Drug Application, Diet, MAT, NDA, Patient, Dietary supplement, Pharmaceutical industry, Sitagliptin

AHMEDABAD, India, Oct. 20, 2023 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as 'Zydus') today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIO™ (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg.

Key Points: 
  • The approval of ZITUVIO™ is based on research, development, regulatory and manufacturing work performed by Zydus teams.
  • ZITUVIO™ has undergone quality testing for Nitrosamines and potential genotoxic impurities as per current USFDA standards.
  • "The ZITUVIO™ approval builds on Zydus' long-term commitment to offer healthcare professionals a new affordable treatment option in connection with diabetes management," said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited.
  • "We are pleased to be able to receive such a milestone approval for Zydus.

Hua Medicine Announces 2023 Interim Results

Retrieved on: 
Friday, August 25, 2023
IGT, DREAM, National Healthcare Security Administration, Rat, Type 2 diabetes, Diabetes, Obesity, Progress, Hong Kong Exchanges and Clearing, Hospital, Patient, NGT, Fructose, American Diabetes Association, ADA, Disease, Pharmacy, Drug discovery, DSM-IV codes, Pancreas, Research, Homeostasis, Kidney, PPG, FKI, Liver, Growth, IND, Fatty liver disease, Endocrinology, DPP-4, Stroke, Chinese University of Hong Kong, MAH, Type 2, Metformin, CUHK, IVD, STA, DKD, Glucokinase, Probability, Metabolism, Liver disease, GK, Nature Communications, SEED, Trial of the century, TIR, Plasma protein binding, GKA, National Healthcare, Physician, AI, Bank, NRDL, Medicine, Congenital hyperinsulinism, Medical device, Pharmaceutical industry, Cryptocurrency, Bayer, T2D

Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").

Key Points: 
  • Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").
  • Dr. Li Chen, the founder and CEO of Hua Medicine, said, "the first half of 2023 was a critical stage for Hua Medicine to begin commercialization.
  • The revenue of Hua Medicine for the first half of 2023 was RMB70.3 million, which was an increase of approximately 299.6% comparing to the second half of 2022.
  • This article contains the statements regarding the future expectations, plans and prospects for Hua Medicine and the investigational product.

Type 2 Diabetes Treatment: Global Market Outlook

Retrieved on: 
Wednesday, January 4, 2023
Death, Jak Airport, Estimation, Glucose, Obesity, Urbanization, Growth, Diabetes, Blood, International Diabetes Federation, Ageing, Science, DPP-4, IDF, Geography, Research, SGLT2, Type 2 diabetes, Pharmaceutical industry, Lithium, Medical device

In this report, the market has been segmented based on route of administration, therapy type and region.The report provides an overview of the global type 2 diabetes treatment market and analyses market trends.

Key Points: 
  • In this report, the market has been segmented based on route of administration, therapy type and region.The report provides an overview of the global type 2 diabetes treatment market and analyses market trends.
  • The report covers the market for type 2 diabetes treatment with regard to the therapy type across different regions.It also highlights major trends and challenges that affect the market and the vendor landscape.
  • It estimates the global market for type 2 diabetes treatment in 2021, and then provides projections for the expected market size through 2027.
  • The global market for type 2 diabetes treatment was estimated to be $REDACTED in 2021.It is projected the type 2 diabetes treatment market will grow at a compound annual growth rate (CAGR) of REDACTED%, and it is forecast to reach $REDACTED by 2027.

Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Markets 2020-2021 & 2026: Focus on Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 20, 2021
Health, Pharmaceutical, DPP-4, Linagliptin, Vildagliptin, Bristol-Myers Squibb Co. v. Superior Court, IDF, Merck & Co., GlaxoSmithKline, Diabetes, Novartis, Growth, Prevalence, E-64, International Diabetes Federation, Anagliptin, Pharmaceutical industry, Fine chemical

The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.

Key Points: 
  • The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.
  • However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market.
  • The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type.
  • Geographically, the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

Poxel Announces Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Retrieved on: 
Friday, September 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Other Health, TWYMEEG (INN: Imeglimin hydrochloride), the TIMES Program, Poxel SA, TWYMEEG (INN: IMEGLIMIN HYDROCHLORIDE), THE TIMES PROGRAM, POXEL SA

TWYMEEG is Poxels first product to reach commercialization and Japan is the first country where the product has been approved.

Key Points: 
  • TWYMEEG is Poxels first product to reach commercialization and Japan is the first country where the product has been approved.
  • Poxel has received a milestone payment of JPY1.75 billion (EUR13.2 million, USD15.8 million)2 from Sumitomo in July for the approval of TWYMEEG.
  • TWYMEEG is a first-in-class drug with a unique dual mechanism of action for the treatment of type 2 diabetes across the continuum of the current treatment paradigm.
  • TWYMEEG (Imeglimin), Poxels first-in-class lead product that targets mitochondrial dysfunction, has been approved for the treatment of type 2 diabetes in Japan.